Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Alkalinization  COVID-19 treatment studies for Alkalinization  C19 studies: Alkalinization  Alkalinization   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 20% Improvement Relative Risk c19early.org/ph Delić et al. NCT04755972 Alkalinization RCT ICU Is very late treatment with alkalinization beneficial for COVID-19? RCT 94 patients in Croatia (October 2020 - June 2021) Lower mortality with alkalinization (not stat. sig., p=0.3) Delić et al., Microorganisms, doi:10.3390/microorganisms10061118 Favors alkalinization Favors control
Effects of Different Inhalation Therapy on Ventilator-Associated Pneumonia in Ventilated COVID-19 Patients: A Randomized Controlled Trial
Delić et al., Effects of Different Inhalation Therapy on Ventilator-Associated Pneumonia in Ventilated COVID-19 Patients: A.., Microorganisms, doi:10.3390/microorganisms10061118, NCT04755972
May 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT mechanically ventilated patients in Croatia, 42 treated with sodium bicarbonate inhalation, and 52 control patients, showing no significant difference in mortality with treatment. Treated patients showed a lower incidence of gram-positive or MRSA-caused ventilator-associated pneumonia.
risk of death, 20.1% lower, RR 0.80, p = 0.30, treatment 20 of 42 (47.6%), control 31 of 52 (59.6%), NNT 8.3.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Delić et al., 28 May 2022, Randomized Controlled Trial, Croatia, peer-reviewed, 12 authors, study period October 2020 - June 2021, trial NCT04755972 (history).
Contact: ndelic@kbsplit.hr (corresponding author), tkljakgas@kbsplit.hr, lsaric@kbsplit.hr, dilic@kbsplit.hr, sdosenovic@kbsplit.hr, jdomazet@kbsplit.hr, rkovac@kbsplit.hr, sastojanovic@kbsplit.hr, bduplanc@kbsplit.hr, andrija.matetic@gmail.com, frane.runjic@gmail.com, josipa.domjanovic@gmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAlkalinizationAll
Abstract: microorganisms Article Effects of Different Inhalation Therapy on Ventilator-Associated Pneumonia in Ventilated COVID-19 Patients: A Randomized Controlled Trial Nikola Delić 1, *, Andrija Matetic 2 , Josipa Domjanović 3 , Toni Kljaković-Gašpić 1 , Lenko Šarić 1 , Darko Ilić 1 , Svjetlana Došenović 1 , Josipa Domazet 1 , Ruben Kovač 1 , Frane Runjić 2 , Sanda Stojanović Stipić 1 and Božidar Duplančić 1 1 2 3 * Citation: Delić, N.; Matetic, A.; Domjanović, J.; Kljaković-Gašpić, T.; Šarić, L.; Ilić, D.; Došenović, S.; Domazet, J.; Kovač, R.; Runjić, F.; et al. Effects of Different Inhalation Therapy on Ventilator-Associated Pneumonia in Ventilated COVID-19 Patients: A Randomized Controlled Trial. Microorganisms 2022, 10, 1118. https://doi.org/10.3390/ microorganisms10061118 Academic Editor: Antonella d’Arminio Monforte Received: 17 March 2022 Accepted: 25 May 2022 Published: 28 May 2022 Department of Anesthesiology, University Hospital of Split, Spinčićeva 1, 21000 Split, Croatia; tkljakgas@kbsplit.hr (T.K.-G.); lsaric@kbsplit.hr (L.Š.); dilic@kbsplit.hr (D.I.); sdosenovic@kbsplit.hr (S.D.); jdomazet@kbsplit.hr (J.D.); rkovac@kbsplit.hr (R.K.); sastojanovic@kbsplit.hr (S.S.S.); bduplanc@kbsplit.hr (B.D.) Department of Cardiology, University Hospital of Split, 21000 Split, Croatia; andrija.matetic@gmail.com (A.M.); frane.runjic@gmail.com (F.R.) Department of Nephrology, University Hospital of Split, 21000 Split, Croatia; josipa.domjanovic@gmail.com Correspondence: ndelic@kbsplit.hr; Tel.: +385-9-8900-0150 Abstract: The effect of routine inhalation therapy on ventilator-associated pneumonia (VAP) in mechanically ventilated patients with the coronavirus disease (COVID-19) has not been well-defined. This randomized controlled trial included 175 eligible adult patients with COVID-19 who were treated with mechanical ventilation at the University Hospital of Split between October 2020 and June 2021. Patients were randomized and allocated to a control group (no routine inhalation) or one of the treatment arms (inhalation of N-acetylcysteine; 5% saline solution; or 8.4% sodium bicarbonate). The primary outcome was the incidence of VAP, while secondary outcomes included all-cause mortality. Routine inhalation therapy had no effect on the incidence of bacterial or fungal VAP nor on all-cause mortality (p > 0.05). Secondary analyses revealed a significant reduction of Gram-positive and methicillin-resistant Staphylococcus aureus (MRSA) VAP in the treatment groups. Specifically, the bicarbonate group had a statistically significantly lower incidence of Gram-positive bacterial VAP (4.8%), followed by the N-acetylcysteine group (10.3%), 5% saline group (19.0%), and control group (34.6%; p = 0.001). This difference was driven by a lower incidence of MRSA VAP in the bicarbonate group (2.4%), followed by the N-acetylcysteine group (7.7%), 5% saline group (14.3%), and control group (34.6%; p < 0.001). Longer duration of ventilator therapy was the only significant, independent predictor of any bacterial or fungal VAP in the multivariate analysis (aOR 1.14, 95% CI 1.01–1.29, p = 0.038 and aOR 1.05, 95% CI 1.01–1.10, p = 0.028, respectively). In conclusion, inhalation therapy had no effect on the overall VAP incidence or all-cause mortality. Further studies should explore the secondary findings of this study such as the reduction of Gram-positive or MRSA-caused VAP in treated patients. Publisher’s Note: MDPI stays neutral with..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit